

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 January 2024 (25.01.2024)



(10) International Publication Number
WO 2024/020083 A3

(51) International Patent Classification:

A61K 38/57 (2006.01) C12N 15/11 (2006.01)
C07K 14/81 (2006.01)

(21) International Application Number:

PCT/US2023/028123

(22) International Filing Date:

19 July 2023 (19.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/390,780 20 July 2022 (20.07.2022) US

(71) Applicant: **BIOCRYST PHARMACEUTICALS, INC.**
[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC
27703 (US).

(72) Inventors: **BABU, Yarlalagadda, S.**; 4836 Southlake Park-
way, Birmingham, AL 35244 (US). **CHEN, Xilin**; 1695
Ridge Haven Run, Alpharetta, GA 30022 (US).

(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, 155
Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: FUSION PROTEIN INHIBITORS OF KLK5

(57) Abstract: Disclosed are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.



WO 2024/020083 A3